

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 May 2003 (15.05.2003)

PCT

(10) International Publication Number
WO 03/040114 A1

(51) International Patent Classification⁷: C07D 263/56, A61K 31/421

(74) Agents: RODNEY, Burton et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(21) International Application Number: PCT/US02/35704

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
6 November 2002 (06.11.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/333,022 6 November 2001 (06.11.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Route 206 and Provinceline Road, Princeton, NJ 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): DEVASTHALE, Pratik [US/US]; 93 Marion Drive, Plainsboro, NJ 08536 (US). JEON, Yoon, T. [US/US]; 10 Saddlewood Court, Belle Mead, NJ 08502 (US).


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTI-OBESITY AGENTS AND METHOD

WO 03/040114 A1



(57) Abstract: Compounds are provided which have the structure (I) wherein Q is C or N, X₁ is CH or N and, A, E, M, G, X₂, X₃, X₄, R¹, R², R^{2a}, R^{2b}, R^{2c}, R³, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND
ANTI OBESITY AGENTS AND METHOD

This application claims priority from U.S.
5 Provisional Application 60/333,022 filed November 6, 2001
which is incorporated herein by reference.


Field of the Invention

10 The present invention relates to novel substituted
acid derivatives which modulate blood glucose levels,
triglyceride levels, insulin levels and non-esterified
fatty acid (NEFA) levels, and thus are particularly
15 useful in the treatment of diabetes and obesity, and to a
method for treating diabetes, especially Type 2 diabetes,
as well as hyperglycemia, hyperinsulinemia,
hyperlipidemia, obesity, atherosclerosis and related
diseases employing such substituted acid derivatives
20 alone or in combination with another antidiabetic agent
and/or a hypolipidemic agent and/or other therapeutic
agents.

Description of the Invention

25 In accordance with the present invention,
substituted acid derivatives are provided which have the
structure I

I



30

wherein m is 0, 1 or 2; n is 0, 1 or 2;

Q is C or N;

A is (CH₂)_x where x is 1 to 5; or A is (CH₂)_x¹ where
x¹ is 2 to 5, with an alkenyl bond or an alkynyl bond

embedded anywhere in the chain; or A is $-(CH_2)_{x^2}-O-(CH_2)_{x^3}-$ where x^2 is 0 to 5 and x^3 is 0 to 5, provided that at least one of x^2 and x^3 is other than 0;

X_1 is CH or N;

5 X_2 is CR^a , NR^b , O or S;

X_3 is CR^c or NR^d ;

X_4 is CR^e , NR^f , O or S, wherein R^a , R^c and R^e are the same or different and are independently selected from a single bond, H, alkyl, alkoxy, aryl, cycloalkyl, amino or substituted amino, and R^b , R^d and R^f are the same or different and are independently selected from a single bond, H, alkyl, aryl, heteroaryl, cycloalkyl or cycloheteroalkyl, provided that at least one of X_2 , X_3 and


10 X_4 is $\begin{array}{c} | \\ -N- \end{array}$;

15 E is O, S, NR^g or CR^h ;

M is NR^i or CR^j ;

G is O, S, NR^k or CR^l , wherein R^g , R^i and R^k are the same or different and are independently selected from a single bond, H, alkyl, aryl, heteroaryl, cycloalkyl or cycloheteroalkyl, and R^h , R^j and R^l are the same or different and are independently selected from a single bond, H, alkyl, alkoxy, aryl, cycloalkyl, amino or substituted amino;

20 provided that at least one of E, M and G is other than CH or C;



and where E, M and G are each $\begin{array}{c} | \\ -N- \end{array}$, then A is other than $-CH_2-O-$; and where in each of X_1 through X_4 as defined above, C may include CH;

R^1 is H or alkyl;

R^2 is H, alkyl, alkoxy, halogen, amino or substituted amino;

R^{2a} , R^{2b} and R^{2c} may be the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;

R^3 is selected from aryloxy-carbonyl,
 5 alkyloxy-carbonyl, alkynyloxy-carbonyl, alkenyloxy-carbonyl, alkyl(halo)aryloxy-carbonyl, alkyloxy(halo)aryloxy-carbonyl, cycloalkylaryloxy-carbonyl, cycloalkyloxyaryloxy-carbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino,
 10 alkoxy-carbonylamino, aryloxy-carbonylamino, heteroaryloxy-carbonylamino, alkylsulfonyl, alkenylsulfonyl, heteroaryloxy-carbonyl, cycloheteroalkyloxy-carbonyl, heteroarylalkenyl, hydroxyalkyl, alkoxy, alkoxyaryloxy-carbonyl,
 15 arylalkyloxy-carbonyl, alkylaryloxy-carbonyl, haloalkoxyaryloxy-carbonyl, alkoxy-carbonylaryloxy-carbonyl, aryloxyaryloxy-carbonyl, heteroaryloxyarylalkyl, aryloxyarylalkyloxy-carbonyl, arylalkenyloxy-carbonyl, aryloxyalkyloxy-carbonyl, arylalkylsulfonyl,
 20 arylthiocarbonyl, arylalkenylsulfonyl, heteroarylsulfonyl, arylsulfonyl, heteroarylalkoxy-carbonyl, heteroarylalkyloxyarylalkyl, arylalkenylarylalkyl, heteroaryloxyarylalkyl, arylalkenylheteroarylalkyl, or polyhaloalkylaryloxy-carbonyl;
 25 carbonyl;


Y is CO_2R^4 (where R^4 is H or alkyl, or a prodrug ester) or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure $P(O)(OR^{4a})R^5$ (R^5 is alkyl or aryl) or a phosphonic acid of the structure $P(O)(OR^{4a})_2$ (where R^{4a} is
 30 H or a prodrug ester);

$(CH_2)_x$, $(CH_2)_{x^1}$, $(CH_2)_{x^2}$, $(CH_2)_{x^3}$, $(CH_2)_m$, and $(CH_2)_n$ may be optionally substituted with 1, 2 or 3 substituents;

including all stereoisomers thereof, prodrug
 35 esters thereof, and pharmaceutically acceptable salts thereof.

Preferred compounds of formula I of the invention have the structure


Ia



5

More preferred are compounds of formula I of the invention having the structure


Ib



10


Still more preferred are compounds of formula I of the invention having the structures

Ic



or


15 Id



In the above compounds, it is preferred that R^{2a} is H or alkoxy, but more preferably H, (CH₂)_x is CH₂, (CH₂)₂,

20 (CH₂)₃, or $\begin{array}{c} \text{CH}_3 \quad \text{CH}_3 \\ | \quad | \\ \text{---C---} \end{array}$, (CH₂)_m is CH₂, or $\begin{array}{c} \text{R}_a \\ | \\ \text{---CH---} \end{array}$ (where R_a is alkyl such as methyl, or alkenyl such as $\text{---CH}_2\text{---CH=CH}_2$ or $\text{---CH}_2\text{---C(=CH}_2\text{)---CH}_2\text{---}$), (CH₂)_n is CH₂, R¹ is lower alkyl, preferably CH₃, R² is H, R^{2a} is H, R⁴ is H, X₁ is CH, and


R^3 is arylalkyloxycarbonyl, aryloxycarbonyl, haloaryl-
 oxycarbonyl, alkoxyaryloxycarbonyl, alkylaryloxycarbonyl,
 aryloxyaryloxycarbonyl, heteroaryloxyarylalkyl,
 heteroaryloxycarbonyl, arylalkenyloxycarbonyl,
 5 cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl,
 arylalkylsulfonyl, arylalkenylsulfonyl, arylthiocarbonyl,
 cycloheteroalkylalkyloxycarbonyl, cycloheteroalkyloxy-
 carbonyl, or polyhaloalkylaryloxycarbonyl, wherein the
 above preferred groups may be optionally substituted,
 10 such as.



where Z is alkoxy, alkyl or halo.


Preferred examples of the group

15





More preferred are compounds of formula I of the
 invention having the structure







20 Ie





Preferred compounds of the invention include the following:









5



10





5

In addition, in accordance with the present invention, a method is provided for treating diabetes, especially Type 2 diabetes, and related diseases such as insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, inflammation, Syndrome X, diabetic complications, dysmetabolic syndrome, atherosclerosis and related diseases wherein a therapeutically effective amount of a compound of structure I is administered to a human patient in need of treatment.

In addition, in accordance with the present invention, a method is provided for treating early malignant lesions (such as ductal carcinoma in situ of the breast and lobular carcinoma in situ of the breast),

pre-malignant lesions (such as fibroadenoma of the breast and prostatic intraepithelial neoplasia (PIN), liposarcomas and various other epithelial tumors (including breast, prostate, colon, ovarian, gastric and lung), irritable bowel syndrome, Crohn's disease, gastric ulceritis, and osteoporosis, and proliferative diseases such as psoriasis, wherein a therapeutically effective amount of a compound of structure I is administered to a human patient in need of treatment.

10 In addition, in accordance with the present invention, a method is provided for treating diabetes and related diseases as defined above and hereinafter, wherein a therapeutically effective amount of a combination of a compound of structure I and another type
15 antidiabetic agent and/or a hypolipidemic agent, and/or lipid modulating agent and/or other type of therapeutic agent, is administered to a human patient in need of treatment.

In the above method of the invention, the compound
20 of structure I will be employed in a weight ratio to the antidiabetic agent (depending upon its mode of operation) within the range from about 0.01:1 to about 100:1, preferably from about 0.5:1 to about 10:1.

25 Detailed Description of the Invention

The conditions, diseases, and maladies collectively referenced to as "Syndrome X" or Dysmetabolic Syndrome (as detailed in Johanson, *J. Clin. Endocrinol. Metab.*, 1997, 82, 727-734, and other
30 publications) include hyperglycemia and/or prediabetic insulin resistance syndrome, and is characterized by an initial insulin resistant state generating hyperinsulinemia, dyslipidemia, and impaired glucose
35 tolerance, which can progress to Type II diabetes, characterized by hyperglycemia, which can progress to diabetic complications.

The term "diabetes and related diseases" refers to Type II diabetes, Type I diabetes, impaired glucose tolerance, obesity, hyperglycemia, Syndrome X, dysmetabolic syndrome, diabetic complications and
5 hyperinsulinemia.

The conditions, diseases and maladies collectively referred to as "diabetic complications" include retinopathy, neuropathy and nephropathy, and other known complications of diabetes.

10 The term "other type(s) of therapeutic agents" as employed herein refers to one or more antidiabetic agents (other than compounds of formula I), one or more anti-obesity agents, and/or one or more lipid-lowering agents, one or more lipid modulating agents (including anti-
15 atherosclerosis agents), and/or one or more antiplatelet agents, one or more agents for treating hypertension, one or more anti-cancer drugs, one or more agents for treating arthritis, one or more anti-osteoporosis agents, one or more anti-obesity agents, one or more agents for
20 treating immunomodulatory diseases, and/or one or more agents for treating anorexia nervosa.

The term "lipid-modulating" agent as employed herein refers to agents which lower LDL and/or raise HDL and/or lower triglycerides and/or lower total cholesterol
25 and/or other known mechanisms for therapeutically treating lipid disorders.

The compounds of the formula I of the present invention may be prepared according to the following general synthetic schemes, as well as relevant published
30 literature procedures that are used by one skilled in the art. Exemplary reagents and procedures for these reactions appear hereinafter and in the working Examples. Protection and deprotection in the Schemes below may be carried out by procedures generally known in the art
35 (see, for example, Greene, T. W. and Wuts, P. G. M., Protecting Groups in Organic Synthesis, 3rd Edition, 1999 [Wiley]).

Scheme 1 describes a general synthesis of carbamate acids IA with a benzoxazole core described in this invention. An alcohol 1 (of which the most preferred is 2-phenyl-5-methyl-oxazole-4-ethanol) is converted to the corresponding nitrile using literature procedures (Aesa, M. et al. Synth. Commun. 1996, 26(5), 909-914) and treated with ethanolic HCl to yield an imide which is condensed with aminophenol 2 (preferably 3-amino-4-hydroxybenzoic acid methyl ester or 4-amino-3-hydroxybenzoic acid methyl ester) under reported conditions (P. D. Edwards et al. J. Med. Chem. 1995, 38, 3972-3982) to afford the corresponding benzoxazoles 3. The methyl ester is transformed, using standard methodology, to aldehyde 4 (Scheme 1). The resulting aldehyde 4 is then subjected to reductive amination using procedures known in the literature (e.g. Abdel-Magid et al, J. Org. Chem. 1996, 61, 3849) with an α -amino ester hydrochloride 5. PG in Scheme 1 denotes a preferred carboxylic acid protecting group, such as a methyl or tert-butyl ester. The resulting secondary amino-ester 6 is then treated with halide 7 such as R^3Cl , preferably a chloroformate, to afford an ester. Final deprotection of the carboxylic acid ester under standard conditions known in the literature (Greene et al supra) utilizing basic conditions (for methyl esters) or acidic conditions (for tert-butyl esters) then furnishes the desired amino acid product IA.

Scheme 2 describes a general synthesis of acid IB with a benzimidazole core. Fluoronitroarene 8 (preferably 4-amino-3-nitrobenzoic acid methyl ester) is reacted with an appropriate amine (R^aNH_2) (where R^a is H, alkyl, aryl, cycloalkyl, heteroaryl or cycloheteroalkyl) to yield nitroaniline ester 9. Ester 9 is transformed, using standard methodology, to aldehyde 10 (Scheme 2). The resulting aldehyde 10 is then subjected to reductive amination as described above for the synthesis of IA in Scheme I. The resulting secondary amino-ester is then

treated with a variety of halides 7, preferably chloroformates, and subjected to hydrogenation to afford 2-aminoaniline 11. The diamine 11 is coupled under EDAC- (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, EDCI or
5 WSC) or BOP-mediated conditions (B. Castro et al, Tetrahedron Lett., 1975, 1219) to afford, after deprotection, the desired benzimidazoles IB.

Scheme 3 describes a general synthesis of carbamate acid IC with a benzofuran core. Iodophenol 12
10 (preferably 3-iodo-4-hydroxybenzaldehyde) is coupled under Pd(II) and Cu₂O-catalyzed conditions (B. Hulin et al. J. Med. Chem. 1996, 39, 3897-3907) with an appropriate acetylene 13 (the preferred acetylene being 5-phenyl-2-methyl-oxazol-4-yl-methylacetylene) to afford
15 benzofuran 14. Following the protocol described above for Scheme I, aldehyde 14 is transformed to acid IC.

Indole-containing acid ID is synthesized from appropriately substituted indole 16 as described in Scheme 4. Indole ester 16 (preferably indole 4-
20 carboxylic acid ester or indole 6-carboxylic acid ester) is reacted with primary mesylate 15 (most preferred mesylate being derived from 2-phenyl-5-methyl-oxazole-4-ethanol or 2-phenyl-5-methyl-oxazole-4-propanol) in the presence of a base such as NaH to afford indole ester 17.
25 Ester 17 is transformed to acid ID in a manner described above for Scheme 1.


Indoles substituted at the 2- and 3- position (IE) are prepared from 2- or 3-iodoindoles 19 via Pd-catalyzed Sonogashira coupling reactions (B. Hulin et al, J. Med.
30 Chem., 1996, 39, 3897-3907) as shown in Scheme 5. Iodoindoles are obtained by procedures known in the literature (Bergman, J. and Venemalm, L.J., Org. Chem., 1992, 57(8), 2495-2497; Fiumana, A. and Jones, K., Chem. Commun., 1999, 17, 1761-2; Murugesan, N. et al, J. Med.
35 Chem. 1998, 40(26), 5198-5218; Kelly, T.A. et al, J. Med. Chem., 1997, 40(15), 2430-2433; Merlic, C.A. et al, Tetrahedron Lett., 1997, 38(39), 6787-6790; Ketcha, D.M.

et al, J. Org. Chem., 1989, 54(18), 4350-4356). The methyl ester 20 is transformed to aldehyde 21 as in Scheme 1 and subjected to reductive amination with glycine ester 5 to yield the secondary aminoester 22.

- 5 Treatment with halide 7 (preferably a chloroformate), followed by reduction of the alkyne and saponification affords the 2- and 3-substituted indoles IE.


- 10 Scheme 6 describes the synthesis of 3-substituted benzofurans and benzothiophenes IF. Compounds IF are prepared in a manner analogous to IE except that 3-bromobenzofurans and 3-bromobenzothiophenes 23 (Horgu, J. et al, Chem. Pharm. Bull., 1998, 46(1), 22-23; Cross, P.E. et al, J. Med. Chem., 1986, 29(9), 1643-1650) are used for the Pd mediated Sonogashira coupling reactions.

15







Scheme 1


In Scheme 1, where E, M and G are each N, then A cannot be $\text{CH}_2\text{-O-}$.




Scheme 2




Scheme 3



Scheme 4

2- and 3-substituted indoles

Scheme 5

3-substituted benzofurans/thiophenes

Scheme 6

Unless otherwise indicated, the term "lower alkyl", "alkyl" or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in the normal chain, and may optionally include an oxygen or nitrogen in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isoheptyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, the various branched chain isomers thereof, and the like as well as such groups including 1 to 4 substituents such as halo, for example F, Br, Cl or I or CF₃, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl, arylalkyloxy, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, hydroxyalkyl, acyl, heteroaryl, heteroaryloxy, cycloheteroalkyl, arylheteroaryl, arylalkoxycarbonyl, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, aryloxyaryl, alkylamido, alkanoylamino, arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl and/or alkylthio and/or any of the R³ groups.

Unless otherwise indicated, the term "cycloalkyl" as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclicalkyl, bicyclicalkyl and tricyclicalkyl, containing a total of 3 to 20 carbons forming the rings, preferably 3 to 10 carbons, forming the ring and which may be fused to 1 or 2 aromatic rings as described for aryl, which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl,

35



any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol and/or alkylthio and/or any of the substituents for alkyl.

The term "cycloalkenyl" as employed herein alone or as part of another group refers to cyclic hydrocarbons containing 3 to 12 carbons, preferably 5 to 10 carbons and 1 or 2 double bonds. Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl, which may be optionally substituted as defined for cycloalkyl.

The term "cycloalkylene" as employed herein refers to a "cycloalkyl" group which includes free bonds and thus is a linking group such as

and the like, and may optionally be substituted as defined above for "cycloalkyl".

The term "alkanoyl" as used herein alone or as part of another group refers to alkyl linked to a carbonyl group.

Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, and may optionally include an oxygen or nitrogen in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-

hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, 5 halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, alkylthio and/or any of the substituents for alkyl set out herein.

10 Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, 15 which include one triple bond in the normal chain, and may optionally include an oxygen or nitrogen in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonyl, 4- 20 decynyl, 3-undecynyl, 4-dodecynyl and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, 25 arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, and/or any of the substituents for alkyl set out herein.

The terms "arylalkenyl" and "arylalkynyl" as used alone or as part of another group refer to alkenyl and alkynyl groups as described above having an aryl 30 substituent.


Where alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed "alkylene" groups and may optionally be substituted as defined above for "alkyl".


35 Where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are

termed "alkenylene groups" and "alkynylene groups", respectively, and may optionally be substituted as defined above for "alkenyl" and "alkynyl".

- (CH₂)_x, (CH₂)_x¹, (CH₂)_x², (CH₂)_x³, (CH₂)_p, (CH₂)_m, or (CH₂)_n includes alkylene, allenyl, alkenylene or alkynylene groups, as defined herein, each of which may optionally include an oxygen or nitrogen in the normal chain, which may optionally include 1, 2, or 3 substituents which include alkyl, alkenyl, halogen, cyano, hydroxy, alkoxy, amino, thioalkyl, keto, C₃-C₆ cycloalkyl, alkylcarbonylamino or alkylcarbonyloxy; the alkyl substituent may be an alkylene moiety of 1 to 4 carbons which may be attached to one or two carbons in the (CH₂)_x, (CH₂)_x¹, (CH₂)_x², (CH₂)_x³ or (CH₂)_m or (CH₂)_n group to form a cycloalkyl group therewith.

Examples of (CH₂)_x, (CH₂)_x¹, (CH₂)_x², (CH₂)_x³, (CH₂)_p, (CH₂)_m, (CH₂)_n, alkylene, alkenylene and alkynylene include







10 The term "halogen" or "halo" as used herein alone or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as CF₃, with chlorine or fluorine being preferred.

15 The term "metal ion" refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth metal ions such as magnesium and calcium, as well as zinc and aluminum.

Unless otherwise indicated, the term "aryl" or the group



20 where Q is C, as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may optionally include one to three
 25 additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings for example



5

and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl-alkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, alkoxycarbonyl, arylcarbonyl, arylalkenyl, aminocarbonylaryl, arylthio, arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl, aryl or any of the other aryl compounds mentioned in the definitions), thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino or arylsulfonaminocarbonyl and/or any of the substituents for alkyl set out herein.

Unless otherwise indicated, the term "lower alkoxy", "alkoxy", "aryloxy" or "aralkoxy" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to an oxygen atom.

Unless otherwise indicated, the term "substituted amino" as employed herein alone or as part of another group refers to amino substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl or thioalkyl. These substituents may be further substituted with a carboxylic acid and/or any of the substituents for alkyl as set out above. In addition, the amino substituents may be taken together with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy.


Unless otherwise indicated, the term "lower alkylthio", "alkylthio", "arylthio" or "aralkylthio" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to a sulfur atom.

Unless otherwise indicated, the term "lower alkylamino", "alkylamino", "arylamino", or "arylalkylamino" as employed herein alone or as part of another group includes any of the above alkyl, aryl or arylalkyl groups linked to a nitrogen atom.

Unless otherwise indicated, the term "acyl" as employed herein by itself or part of another group, as defined herein, refers to an organic radical linked to a carbonyl $\left(\begin{smallmatrix} \text{O} \\ \parallel \\ \text{C} \end{smallmatrix} \right)$ group; examples of acyl groups include any of the R^3 groups attached to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl, cycloalkanoyl, cycloheteroalkanoyl and the like.

Unless otherwise indicated, the term "cycloheteroalkyl" as used herein alone or as part of


another group refers to a 5-, 6- or 7-membered saturated or partially unsaturated ring which includes 1 to 2 hetero atoms such as nitrogen, oxygen and/or sulfur, linked through a carbon atom or a heteroatom, where possible, optionally via the linker $(CH_2)_p$ (where p is 1, 2 or 3), such as



15


and the like. The above groups may include 1 to 4 substituents such as alkyl, halo, oxo and/or any of of the substituents for alkyl or aryl set out herein. In addition, any of the cycloheteroalkyl rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.

Unless otherwise indicated, the term "heteroaryl" as used herein alone or as part of another group refers to a 5- or 6- membered aromatic ring including




where Q is N, which includes 1, 2, 3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl; indolyl), and includes

possible N-oxides. The heteroaryl group may optionally include 1 to 4 substituents such as any of the the substituents for alkyl or aryl set out above. Examples of heteroaryl groups include the following:




and the like.

15 Examples of



groups include, but are not limited to:




The term "cycloheteroalkylalkyl" as used herein alone or as part of another group refers to
 5 cycloheteroalkyl groups as defined above linked through a C atom or heteroatom to an alkylene or alkenylene as defined above.

The term "heteroarylalkyl" or "heteroarylalkenyl" as used herein alone or as part of another group refers
 10 to a heteroaryl group as defined above linked through a C atom or heteroatom to an alkylene or alkenylene as defined above.

The term "polyhaloalkyl" as used herein refers to an "alkyl" group as defined above which includes from 2
 15 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF₃CH₂, CF₃ or CF₃CF₂CH₂.


The term "polyhaloalkyloxy" as used herein refers to an "alkoxy" or "alkyloxy" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo
 20 substituents, such as F or Cl, preferably F, such as CF₃CH₂O, CF₃O or CF₃CF₂CH₂O.

The term "prodrug esters" as employed herein includes prodrug esters which are known in the art for carboxylic and phosphorus acid esters such as methyl,
 25 ethyl, benzyl and the like. Other prodrug ester examples of R⁴ include the following groups:
 (1-alkanoyloxy)alkyl such as,




wherein R^a , R^b and R^c are H, alkyl, aryl or arylalkyl; however, R^{aO} cannot be HO.

- 5 Examples of such prodrug esters R^4 include



Other examples of suitable prodrug esters R^4 include

- 10



- 15 wherein R^a can be H, alkyl (such as methyl or t-butyl), arylalkyl (such as benzyl) or aryl (such as phenyl); R^d is H, alkyl, halogen or alkoxy, R^e is alkyl, aryl, arylalkyl or alkoxy, and n₁ is 0, 1 or 2.

Where the compounds of structure I are in acid form they may form a pharmaceutically acceptable salt such as alkali metal salts such as lithium, sodium or potassium, alkaline earth metal salts such as calcium or magnesium as well as zinc or aluminum and other cations such as ammonium, choline, diethanolamine, lysine (D or L), ethylenediamine, t-butylamine, t-octylamine, tris-(hydroxymethyl)aminomethane (TRIS), N-methyl glucosamine (NMG), triethanolamine and dehydroabietylamine.

All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of the carbon atoms including any one or the R substituents. Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The processes for preparation can utilize racemates, enantiomers or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization.

Where desired, the compounds of structure I may be used in combination with one or more hypolipidemic agents or lipid-lowering agents or lipid modulating agents and/or one or more other types of therapeutic agents including antidiabetic agents, anti-obesity agents, antihypertensive agents, platelet aggregation inhibitors, and/or anti-osteoporosis agents, which may be administered orally in the same dosage form, in a separate oral dosage form or by injection.

The hypolipidemic agent or lipid-lowering agent or lipid modulating agents which may be optionally employed in combination with the compounds of formula I of the invention may include 1,2,3 or more MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, fibric acid derivatives, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na⁺/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, bile acid sequestrants, and/or nicotinic acid and derivatives thereof.


MTP inhibitors employed herein include MTP inhibitors disclosed in U.S. Patent No. 5,595,872, U.S. Patent No. 5,739,135, U.S. Patent No. 5,712,279, U.S. Patent No. 5,760,246, U.S. Patent No. 5,827,875, U.S. Patent No. 5,885,983 and U.S. Application Serial No.

09/175,180 filed October 20, 1998, now U.S. Patent No. 5,962,440. Preferred are each of the preferred MTP inhibitors disclosed in each of the above patents and applications.

5 All of the above U.S. Patents and applications are incorporated herein by reference.

Most preferred MTP inhibitors to be employed in accordance with the present invention include preferred MTP inhibitors as set out in U.S. Patent Nos. 5,739,135
10 and 5,712,279, and U.S. Patent No. 5,760,246.

The most preferred MTP inhibitor is 9-[4-[4-[[2-(2,2,2-Trifluoroethoxy)benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide



15

The hypolipidemic agent may be an HMG CoA reductase inhibitor which includes, but is not limited to, mevastatin and related compounds as disclosed in U.S. Patent No. 3,983,140, lovastatin (mevinolin) and related
20 compounds as disclosed in U.S. Patent No. 4,231,938, pravastatin and related compounds such as disclosed in U.S. Patent No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Patent Nos. 4,448,784 and 4,450,171. Other HMG CoA reductase inhibitors which may
25 be employed herein include, but are not limited to, fluvastatin, disclosed in U.S. Patent No. 5,354,772, cerivastatin disclosed in U.S. Patent Nos. 5,006,530 and 5,177,080, atorvastatin disclosed in U.S. Patent Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104,
30 itavastatin (Nissan/Sankyo's nisvastatin (NK-104))

- disclosed in U.S. Patent No. 5,011,930, Shionogi-Astra/Zeneca visastatin (ZD-4522) disclosed in U.S. Patent No. 5,260,440, and related statin compounds disclosed in U.S. Patent No. 5,753,675, pyrazole analogs of mevalonolactone derivatives as disclosed in U.S. Patent No. 4,613,610, indene analogs of mevalonolactone derivatives as disclosed in PCT application WO 86/03488, 6-[2-(substituted-pyrrol-1-yl)-alkyl]pyran-2-ones and derivatives thereof as disclosed in U.S. Patent No. 4,647,576, Searle's SC-45355 (a 3-substituted pentanedioic acid derivative) dichloroacetate, imidazole analogs of mevalonolactone as disclosed in PCT application WO 86/07054, 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives as disclosed in French Patent No. 2,596,393, 2,3-disubstituted pyrrole, furan and thiophene derivatives as disclosed in European Patent Application No. 0221025, naphthyl analogs of mevalonolactone as disclosed in U.S. Patent No. 4,686,237, octahydronaphthalenes such as disclosed in U.S. Patent No. 4,499,289, keto analogs of mevinolin (lovastatin) as disclosed in European Patent Application No. 0,142,146 A2, and quinoline and pyridine derivatives disclosed in U.S. Patent No. 5,506,219 and 5,691,322.

- In addition, phosphinic acid compounds useful in inhibiting HMG CoA reductase suitable for use herein are disclosed in GB 2205837.

- The squalene synthetase inhibitors suitable for use herein include, but are not limited to, α -phosphonosulfonates disclosed in U.S. Patent No. 5,712,396, those disclosed by Biller et al, J. Med. Chem., 1988, Vol. 31, No. 10, pp 1869-1871, including isoprenoid (phosphinylmethyl)phosphonates as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Patent No. 4,871,721 and 4,924,024 and in Biller, S.A., Neuenschwander, K., Ponpipom, M.M., and Poulter, C.D., Current Pharmaceutical Design, 2, 1-40 (1996).

In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al, J. Med. Chem., 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc., 1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R.W. et al, J.A.C.S., 1987, 109, 5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, Summary.

Other hypolipidemic agents suitable for use herein include, but are not limited to, fibric acid derivatives, such as fenofibrate, gemfibrozil, clofibrate, bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds as disclosed in U.S. Patent No. 3,674,836, probucol and gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (Secholex®, Policexide®) and cholestagel (Sankyo/Geltex), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid (niacin), acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives such as disclosed in U.S. Patent No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U.S. Patent No. 4,027,009, and other known serum cholesterol lowering agents.

The hypolipidemic agent may be an ACAT inhibitor such as disclosed in, Drugs of the Future 24, 9-15

- (1999), (Avasimibe); "The ACAT inhibitor, Cl-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Nicolosi et al, Atherosclerosis (Shannon, Irel). (1998), 137(1), 77-85;
- 5 "The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein", Ghiselli, Giancarlo, Cardiovasc. Drug-Rev. (1998), 16(1), 16-30; "RP 73163: a
- 10 bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor", Smith, C., et al, Bioorg. Med. Chem. Lett. (1996), 6(1), 47-50; "ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic activities in experimental animals", Krause et al,
- 15 Editor(s): Ruffolo, Robert R., Jr.; Hollinger, Manfred A., Inflammation: Mediators Pathways (1995), 173-98, Publisher: CRC, Boca Raton, Fla.; "ACAT inhibitors: potential anti-atherosclerotic agents", Sliskovic et al, Curr. Med. Chem. (1994), 1(3), 204-25; "Inhibitors of
- 20 acyl-CoA:cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-(1-
- 25 phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity", Stout et al, Chemtracts: Org. Chem. (1995), 8(6), 359-62, or TS-962 (Taisho Pharmaceutical Co. Ltd).

The hypolipidemic agent may be an upregulator of

30 LD2 receptor activity such as MD-700 (Taisho Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly).

The hypolipidemic agent may be a cholesterol absorption inhibitor preferably Schering-Plough's SCH48461 as well as those disclosed in Atherosclerosis

35 115, 45-63 (1995) and J. Med. Chem. 41, 973 (1998).

The hypolipidemic agent may be an ileal Na⁺/bile acid cotransporter inhibitor such as disclosed in Drugs of the Future, 24, 425-430 (1999).

5 The lipid-modulating agent may be a cholesteryl ester transfer protein (CETP) inhibitor such as Pfizer's CP 529,414 (WO/0038722 and EP 818448) and Pharmacia's SC-744 and SC-795.

10 The ATP citrate lyase inhibitor which may be employed in the combination of the invention may include, for example, those disclosed in U.S. Patent No. 5,447,954.

Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, itavastatin and visastatin and ZD-4522.

15 The above-mentioned U.S. patents are incorporated herein by reference. The amounts and dosages employed will be as indicated in the Physician's Desk Reference and/or in the patents set out above.

20 The compounds of formula I of the invention will be employed in a weight ratio to the hypolipidemic agent (were present), within the range from about 500:1 to about 1:500, preferably from about 100:1 to about 1:100.

25 The dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.

The dosages and formulations for the hypolipidemic agent will be as disclosed in the various patents and applications discussed above.

30 The dosages and formulations for the other hypolipidemic agent to be employed, where applicable, will be as set out in the latest edition of the Physicians' Desk Reference.

35 For oral administration, a satisfactory result may be obtained employing the MTP inhibitor in an amount within the range of from about 0.01 mg to about 500 mg

and preferably from about 0.1 mg to about 100 mg, one to four times daily.

A preferred oral dosage form, such as tablets or capsules, will contain the MTP inhibitor in an amount of
5 from about 1 to about 500 mg, preferably from about 2 to about 400 mg, and more preferably from about 5 to about 250 mg, one to four times daily.

For oral administration, a satisfactory result may be obtained employing an HMG CoA reductase inhibitor, for
10 example, pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin in dosages employed as indicated in the Physician's Desk Reference, such as in an amount within the range of from about 1 to 2000 mg, and preferably from about 4 to about 200 mg.

15 The squalene synthetase inhibitor may be employed in dosages in an amount within the range of from about 10 mg to about 2000 mg and preferably from about 25 mg to about 200 mg.

A preferred oral dosage form, such as tablets or
20 capsules, will contain the HMG CoA reductase inhibitor in an amount from about 0.1 to about 100 mg, preferably from about 0.5 to about 80 mg, and more preferably from about 1 to about 40 mg.

A preferred oral dosage form, such as tablets or
25 capsules will contain the squalene synthetase inhibitor in an amount of from about 10 to about 500 mg, preferably from about 25 to about 200 mg.

The hypolipidemic agent may also be a lipoxygenase inhibitor including a 15-lipoxygenase (15-LO) inhibitor
30 such as benzimidazole derivatives as disclosed in WO 97/12615, 15-LO inhibitors as disclosed in WO 97/12613, isothiazolones as disclosed in WO 96/38144, and 15-LO inhibitors as disclosed by Sendobry et al "Attenuation of diet-induced atherosclerosis in rabbits with a highly
35 selective 15-lipoxygenase inhibitor lacking significant antioxidant properties", Brit. J. Pharmacology (1997) 120, 1199-1206, and Cornicelli et al, "15-Lipoxygenase

and its Inhibition: A Novel Therapeutic Target for Vascular Disease", Current Pharmaceutical Design, 1999, 5, 11-20.

5 The compounds of formula I and the hypolipidemic agent may be employed together in the same oral dosage form or in separate oral dosage forms taken at the same time.

10 The compositions described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be advisable to start a patient on a low dose combination and work up gradually to a high dose combination.

15 The preferred hypolipidemic agent is pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin or cerivastatin as well as niacin and/or cholestagel.

20 The other antidiabetic agent which may be optionally employed in combination with the compound of formula I may be 1,2,3 or more antidiabetic agents or antihyperglycemic agents including insulin secretagogues or insulin sensitizers, or other antidiabetic agents preferably having a mechanism of action different from the compounds of formula I of the invention, which may include biguanides, sulfonyl ureas, glucosidase
25 inhibitors, PPAR γ agonists, such as thiazolidinediones, α P2 inhibitors, dipeptidyl peptidase IV (DP4) inhibitors, SGLT2 inhibitors, and/or meglitinides, as well as insulin, and/or glucagon-like peptide-1 (GLP-1).

30 The other antidiabetic agent may be an oral antihyperglycemic agent preferably a biguanide such as metformin or phenformin or salts thereof, preferably metformin HCl.

35 Where the antidiabetic agent is a biguanide, the compounds of structure I will be employed in a weight ratio to biguanide within the range from about 0.001:1 to about 10:1, preferably from about 0.01:1 to about 5:1.

The other antidiabetic agent may also preferably be a sulfonyl urea such as glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Patent No. 4,379,785), glipizide, gliclazide or chlorpropamide, 5 other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the β -cells, with glyburide and glipizide being preferred, which may be administered in the same or in separate oral dosage forms.

10 The compounds of structure I will be employed in a weight ratio to the sulfonyl urea in the range from about 0.01:1 to about 100:1, preferably from about 0.02:1 to about 5:1.

The oral antidiabetic agent may also be a 15 glucosidase inhibitor such as acarbose (disclosed in U.S. Patent No. 4,904,769) or miglitol (disclosed in U.S. Patent No. 4,639,436), which may be administered in the same or in a separate oral dosage forms.

20 The compounds of structure I will be employed in a weight ratio to the glucosidase inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.05:1 to about 10:1.

The compounds of structure I may be employed in combination with a PPAR γ agonist such as a 25 thiazolidinedione oral anti-diabetic agent or other insulin sensitizers (which has an insulin sensitivity effect in NIDDM patients) such as troglitazone (Warner-Lambert's Rezulin®, disclosed in U.S. Patent No. 4,572,912), rosiglitazone (SKB), pioglitazone (Takeda), 30 Mitsubishi's MCC-555 (disclosed in U.S. Patent No. 5,594,016), Glaxo-Welcome's GL-262570, englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer, isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), NN-2344 (Dr. Reddy/NN), or 35 YM-440 (Yamanouchi), preferably rosiglitazone and pioglitazone.

The compounds of structure I will be employed in a weight ratio to the thiazolidinedione in an amount within the range from about 0.01:1 to about 100:1, preferably from about 0.05 to about 10:1.

5 The sulfonyl urea and thiazolidinedione in amounts of less than about 150 mg oral antidiabetic agent may be incorporated in a single tablet with the compounds of structure I.

10 The compounds of structure I may also be employed in combination with a antihyperglycemic agent such as insulin or with glucagon-like peptide-1 (GLP-1) such as GLP-1(1-36) amide, GLP-1(7-36) amide, GLP-1(7-37) (as disclosed in U.S. Patent No. 5,614,492 to Habener, the disclosure of which is incorporated herein by reference),
15 as well as AC2993 (Amylin) and LY-315902 (Lilly), which may be administered via injection, intranasal, inhalation or by transdermal or buccal devices.

Where present, metformin, the sulfonyl ureas, such as glyburide, glimepiride, glipyrider, glipizide,
20 chlorpropamide and gliclazide and the glucosidase inhibitors acarbose or miglitol or insulin (injectable, pulmonary, buccal, or oral) may be employed in formulations as described above and in amounts and dosing as indicated in the Physician's Desk Reference (PDR).

25 Where present, metformin or salt thereof may be employed in amounts within the range from about 500 to about 2000 mg per day which may be administered in single or divided doses one to four times daily.

Where present, the thiazolidinedione anti-diabetic
30 agent may be employed in amounts within the range from about 0.01 to about 2000 mg/day which may be administered in single or divided doses one to four times per day.

Where present insulin may be employed in formulations, amounts and dosing as indicated by the
35 Physician's Desk Reference.

Where present GLP-1 peptides may be administered in oral buccal formulations, by nasal administration or

parenterally as described in U.S. Patent Nos. 5,346,701 (TheraTech), 5,614,492 and 5,631,224 which are incorporated herein by reference.

The other antidiabetic agent may also be a PPAR α/γ dual agonist such as AR-H039242 (Astra/Zeneca), GW-409544 (Glaxo-Wellcome), KRP297 (Kyorin Merck) as well as those disclosed by Murakami et al, "A Novel Insulin Sensitizer Acts As a Coligand for Peroxisome Proliferation - Activated Receptor Alpha (PPAR-alpha) and PPAR gamma.

10 Effect on PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes 47, 1841-1847 (1998).

The antidiabetic agent may be an SGLT2 inhibitor such as disclosed in U.S. application Serial No. 09/679,027, filed October 4, 2000 (attorney file LA49 NP), employing dosages as set out therein. Preferred are the compounds designated as preferred in the above application.

The antidiabetic agent may be an $\alpha P2$ inhibitor such as disclosed in U.S. application Serial No. 09/391,053, filed September 7, 1999, and in U.S. application Serial No. 09/519,079, filed March 6, 2000 (attorney file LA27 NP), employing dosages as set out herein. Preferred are the compounds designated as preferred in the above application.

The antidiabetic agent may be a DP4 inhibitor such as disclosed in U.S. application Serial No. 09/788,173 filed February 16, 2001 (attorney file LA50), WO99/38501, WO99/46272, WO99/67279 (PROBIODRUG), WO99/67278 (PROBIODRUG), WO99/61431 (PROBIODRUG), NVP-DPP728A (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine) (Novartis) (preferred) as disclosed by Hughes et al, Biochemistry, 38(36), 11597-11603, 1999, TSL-225 (tryptophyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid (disclosed by Yamada et al, Bioorg. & Med. Chem. Lett. 8 (1998) 1537-1540, 2-cyanopyrrolidides and 4-cyanopyrrolidides as disclosed by

Ashworth et al, Bioorg. & Med. Chem. Lett., Vol. 6, No. 22, pp 1163-1166 and 2745-2748 (1996) employing dosages as set out in the above references.

5 The meglitinide which may optionally be employed in combination with the compound of formula I of the invention may be repaglinide, nateglinide (Novartis) or KAD1229 (PF/Kissei), with repaglinide being preferred.

The compound of formula I will be employed in a weight-ratio to the meglitinide, PPAR- γ -agonist, PPAR- α/γ dual agonist, aP2 inhibitor, DP4 inhibitor or SGLT2 inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.05 to about 10:1.

15 The other type of therapeutic agent which may be optionally employed with a compound of formula I may be 1, 2, 3 or more of an anti-obesity agent including a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, an aP2 inhibitor, a thyroid receptor agonist and/or an anorectic agent.

The beta 3 adrenergic agonist which may be optionally employed in combination with a compound of formula I may be AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, with 25 AJ9677, L750,355 and CP331648 being preferred.

The lipase inhibitor which may be optionally employed in combination with a compound of formula I may be orlistat or ATL-962 (Alizyme), with orlistat being preferred.

30 The serotonin (and dopamine) reuptake inhibitor which may be optionally employed in combination with a compound of formula I may be sibutramine, topiramate (Johnson & Johnson) or axokine (Regeneron), with sibutramine and topiramate being preferred.

35 The thyroid receptor agonist which may be optionally employed in combination with a compound of formula I may be a thyroid receptor ligand as disclosed

in WO97/21993 (U. Cal SF), WO99/00353 (KaroBio), GB98/284425 (KaroBio), and U.S. Provisional Application 60/183,223 filed February 17, 2000, with compounds of the KaroBio applications and the above U.S. provisional application being preferred.

The anorectic agent which may be optionally employed in combination with a compound of formula I may be dexamphetamine, phentermine, phenylpropanolamine or mazindol, with dexamphetamine being preferred.

The various anti-obesity agents described above may be employed in the same dosage form with the compound of formula I or in different dosage forms, in dosages and regimens as generally known in the art or in the PDR.

The antihypertensive agents which may be employed in combination with the compound of formula I of the invention include ACE inhibitors, angiotensin II receptor antagonists, NEP/ACE inhibitors, as well as calcium channel blockers, β -adrenergic blockers and other types of antihypertensive agents including diuretics.

The angiotensin converting enzyme inhibitor which may be employed herein includes those containing a mercapto (-S-) moiety such as substituted proline derivatives, such as any of those disclosed in U.S. Pat. No. 4,046,889 to Ondetti et al mentioned above, with captopril, that is, 1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline, being preferred, and mercaptoacyl derivatives of substituted prolines such as any of those disclosed in U.S. Pat. No. 4,316,906 with zofenopril being preferred.

Other examples of mercapto containing ACE inhibitors that may be employed herein include rentiapril (fentiapril, Santen) disclosed in Clin. Exp. Pharmacol. Physiol. 10:131 (1983); as well as pivopril and YS980.

Other examples of angiotensin converting enzyme inhibitors which may be employed herein include any of those disclosed in U.S. Pat. No. 4,374,829 mentioned above, with N-(1-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-

L-proline, that is, enalapril, being preferred, any of the phosphonate substituted amino or imino acids or salts disclosed in U.S. Pat. No. 4,452,790 with (S)-1-[6-amino-2-[[hydroxy-(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline or (ceronapril) being preferred,
5 phosphinylalkanoyl prolines disclosed in U.S. Pat. No. 4,168,267 mentioned above with fosinopril being preferred, any of the phosphinylalkanoyl substituted prolines disclosed in U.S. Pat. No. 4,337,201, and the
10 phosphonamides disclosed in U.S. Pat. No. 4,432,971 discussed above.

Other examples of ACE inhibitors that may be employed herein include Beecham's BRL 36,378 as disclosed in European Patent Application Nos. 80822 and 60668;
15 Chugai's MC-838 disclosed in C.A. 102:72588v and Jap. J. Pharmacol. 40:373 (1986); Ciba-Geigy's CGS 14824 (3-([1-ethoxycarbonyl-3-phenyl-(1S)-propyl]amino)-2,3,4,5-tetrahydro-2-oxo-1-(3S)-benzazepine-1 acetic acid HCl) disclosed in U.K. Patent No. 2103614 and CGS 16,617
20 (3(S)-[[(1S)-5-amino-1-carboxypentyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-ethanoic acid) disclosed in U.S. Pat. No. 4,473,575; cetapril (alacepril, Dainippon) disclosed in Eur. Therap. Res. 39:671 (1986); 40:543 (1986); ramipril (Hoechst)
25 disclosed in Euro. Patent No. 79-022 and Curr. Ther. Res. 40:74 (1986); Ru 44570 (Hoechst) disclosed in Arzneimittelforschung 34:1254 (1985), cilazapril (Hoffman-LaRoche) disclosed in J. Cardiovasc. Pharmacol. 9:39 (1987); R 31-2201 (Hoffman-LaRoche) disclosed in
30 FEBS Lett. 165:201 (1984); lisinopril (Merck), indalaprill (delapril) disclosed in U.S. Pat. No. 4,385,051; indolapril (Schering) disclosed in J. Cardiovasc. Pharmacol. 5:643, 655 (1983), spirapril (Schering) disclosed in Acta. Pharmacol. Toxicol. 59 (Supp. 5):173
35 (1986); perindopril (Servier) disclosed in Eur. J. clin. Pharmacol. 31:519 (1987); quinapril (Warner-Lambert) disclosed in U.S. Pat. No. 4,344,949 and CI925 (Warner-

Lambert) ([3S-[2[R(*)R(*)]]3R(*)]-2-[2-[[1-(ethoxy-carbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid HCl) disclosed in Pharmacologist 26:243, 266 (1984), WY-44221 (Wyeth) disclosed in J. Med. Chem. 26:394 (1983).

Preferred ACE inhibitors are captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril and moexipril.

NEP/ACE inhibitors may also be employed herein in that they possess neutral endopeptidase (NEP) inhibitory activity and angiotensin converting enzyme (ACE) inhibitory activity. Examples of NEP/ACE inhibitors suitable for use herein include those disclosed in U.S. Pat. Nos. 5,362,727, 5,366,973, 5,225,401, 4,722,810, 5,223,516, 4,749,688, U.S. Patent. No. 5,552,397, U.S. Pat. No. 5,504,080, U.S. Patent No. 5,612,359, U.S. Pat. No. 5,525,723, European Patent Application 0599,444, 0481,522, 0599,444, 0595,610, European Patent Application 0534363A2, 534,396 and 534,492, and European Patent Application 0629627A2.

Preferred are those NEP/ACE inhibitors and dosages thereof which are designated as preferred in the above patents/applications which U.S. patents are incorporated herein by reference; most preferred are omapatrilat, BMS 189,921 ([S-(R*,R*)]-hexahydro-6-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid (gemopatrilat)), CGS 30440 and MD100240 (Aventis).

The angiotensin II receptor antagonist (also referred to herein as angiotensin II antagonist or AII antagonist) suitable for use herein includes, but is not limited to, irbesartan, losartan, valsartan, candesartan, telmisartan, tasosartan or eprosartan, with irbesartan, losartan or valsartan being preferred.

A preferred oral dosage form, such as tablets or capsules, will contain the ACE inhibitor or AII antagonist in an amount within the range from about 0.1 to

about 500 mg, preferably from about 5 to about 200 mg and more preferably from about 10 to about 150 mg.

For parenteral administration, the ACE inhibitor, angiotensin II antagonist or NEP/ACE inhibitor will be employed in an amount within the range from about 0.005 mg/kg to about 10 mg/kg and preferably from about 0.01 mg/kg to about 1 mg/kg.

Where a drug is to be administered intravenously, it will be formulated in conventional vehicles, such as distilled water, saline, Ringer's solution or other conventional carriers.

It will be appreciated that preferred dosages of ACE inhibitor and AII antagonist as well as other antihypertensives disclosed herein will be as set out in the latest edition of the Physician's Desk Reference (PDR).

Other examples of preferred antihypertensive agents suitable for use herein include omapatrilat (Vanlev®), amlodipine besylate (Norvasc®), prazosin HCl (Minipress®), verapamil, nifedipine, nadolol, diltiazem, felodipine, nisoldipine, isradipine, nicardipine, atenolol, carvedilol, sotalol, terazosin, doxazosin, propranolol, and clonidine HCl (Catapres®).

Diuretics which may be employed in combination with compounds of formula I include hydrochlorothiazide, torasemide, furosemide, spironolactone, and indapamide.

Antiplatelet agents which may be employed in combination with compounds of formula I of the invention include aspirin, clopidogrel, ticlopidine, dipyridamole, abciximab, tirofiban, eptifibatide, anagrelide, and ifetroban, with clopidogrel and aspirin being preferred.

The antiplatelet drugs may be employed in amounts as indicated in the PDR. Ifetroban may be employed in amounts as set out in U.S. Patent No. 5,100,889.

Antiosteoporosis agents suitable for use herein in combination with the compounds of formula I of the invention include parathyroid hormone or bisphosphonates,

such as MK-217 (alendronate) (Fosamax®). Dosages employed will be as set out in the PDR.

In carrying out the method of the invention, a pharmaceutical composition will be employed containing
5 the compounds of structure I, with or without another therapeutic agent, in association with a pharmaceutical vehicle or diluent. The pharmaceutical composition can be formulated employing conventional solid or liquid
10 vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration. The compounds can be administered to mammalian species including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, granules or powders, or they can be administered by a parenteral
15 route in the form of injectable preparations. The dose for adults is preferably between 50 and 2,000 mg per day, which can be administered in a single dose or in the form of individual doses from 1-4 times per day.

A typical capsule for oral administration contains
20 compounds of structure I (250 mg), lactose (75 mg) and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.

A typical injectable preparation is produced by
25 aseptically placing 250 mg of compounds of structure I into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable
30 preparation.

The following Examples represent preferred embodiments of the invention.

The following abbreviations are employed in the
35 Examples:

Ph = phenyl

Bn = benzyl

- t-Bu = tertiary butyl
Me = methyl
Et = ethyl
TMS = trimethylsilyl
5 TMSN₃ = trimethylsilyl azide
TBS = tert-butyldimethylsilyl
Fmoc = fluorenylmethoxycarbonyl
Boc = tert-butoxycarbonyl
Cbz = carbobenzyloxy or carbobenzoxy or benzyloxycarbonyl
10 THF = tetrahydrofuran
Et₂O = diethyl ether
hex = hexanes
EtOAc = ethyl acetate
DMF = dimethyl formamide
15 MeOH = methanol
EtOH = ethanol
i-PrOH = isopropanol
DMSO = dimethyl sulfoxide
DME = 1,2 dimethoxyethane
20 DCE = 1,2 dichloroethane
HMPA = hexamethyl phosphoric triamide
HOAc or AcOH = acetic acid
Ac = acetyl
TFA = trifluoroacetic acid
25 TFAA = trifluoroacetic anhydride
i-Pr₂NEt = diisopropylethylamine
Et₃N = triethylamine
NMM = N-methyl morpholine
DMAP = 4-dimethylaminopyridine
30 NaBH₄ = sodium borohydride
NaBH(OAc)₃ = sodium triacetoxymborohydride
DIBALH = diisobutyl aluminum hydride
LiAlH₄ = lithium aluminum hydride
n-BuLi = n-butyllithium
35 Pd/C = palladium on carbon

- PtO₂ = platinum oxide
KOH = potassium hydroxide
NaOH = sodium hydroxide
LiOH = lithium hydroxide
- 5 K₂CO₃ = potassium carbonate
NaHCO₃ = sodium bicarbonate
DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene
EDC (or EDC.HCl) or EDCI (or EDCI.HCl) or EDAC = 3-ethyl-
3'-(dimethylamino)propyl- carbodiimide hydrochloride (or
10 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride)
HOBT or HOBT.H₂O = 1-hydroxybenzotriazole hydrate
HOAT = 1-Hydroxy-7-azabenzotriazole
BOP reagent = benzotriazol-1-yloxy-tris (dimethylamino)
15 phosphonium hexafluorophosphate
NaN(TMS)₂ = sodium hexamethyldisilazide or sodium
bis(trimethylsilyl)amide
Ph₃P = triphenylphosphine
Pd(OAc)₂ = Palladium acetate
20 (Ph₃P)₄Pd⁰ = tetrakis triphenylphosphine palladium
DEAD = diethyl azodicarboxylate
DIAD = diisopropyl azodicarboxylate
Cbz-Cl = benzyl chloroformate
CAN = ceric ammonium nitrate
25 SAX = Strong Anion Exchanger
SCX = Strong Cation Exchanger
Ar = argon
N₂ = nitrogen
min = minute(s)
30 h or hr = hour(s)
L = liter
mL = milliliter
μL = microliter
g = gram(s)
35 mg = milligram(s)

mol = moles

mmol = millimole(s)

meq = milliequivalent

RT = room temperature

5 sat or sat'd = saturated

aq. = aqueous

TLC = thin layer chromatography

HPLC = high performance liquid chromatography

LC/MS = high performance liquid chromatography/mass

10 spectrometry

MS or Mass Spec = mass spectrometry

NMR = nuclear magnetic resonance


NMR spectral data: s = singlet; d = doublet; m =
multiplet; br = broad; t = triplet

15 mp = melting point


The following Examples represent preferred
embodiments of the invention.

20

Example 1



A.




25

To a solution of 2-(5-methyl-2-phenyl-4-oxazolyl)ethanol (Maybridge, 10 gm, 49.3 mmol), acetone cyanohydrin (6.3 gm, 74 mmol), Ph_3P (12.9 gm, 49.2 mmol) in 25 ml THF at 0°C was added DEAD (12.9 gm, 1.5 mmol) dropwise. The reaction mixture was allowed to warm to rt and stirred overnight. Evaporation followed by

purification by flash chromatography (30% EtOAc:hexanes) yielded 2.69 gm pure product (Part A compound) + 5.9 gm impure fractions (total yield: approx 75-80%).

5

B.



Reference: P. D. Edwards et al. J. Med. Chem. 1995, 38, 3972-3982.

10

A solution of anhydrous EtOH (1 ml) in CHCl_3 (2 ml) at 0°C was treated with AcCl (1 ml) followed by Part A compound (178 mg, 0.84 mmol) in CHCl_3 (1 ml). The mixture was allowed to warm to rt and stirred for a total of 4 h. Solvents were evaporated to yield a pale yellow foam.


15

The foam was dissolved in EtOH (3 ml) and to this solution was added 3-amino-4-hydroxybenzoic acid methyl ester hydrochloride (180 mg, 0.885 mmol) followed by Et_3N (200 μl , 1.44 mmol). The mixture was heated to 60°C for 4h, diluted with EtOAc, washed with 1N HCl, 1N NaOH,

20

brine, dried (Na_2SO_4), evaporated, and purified by flash chromatography (30% to 40% EtOAc:hexanes) to yield a colorless, fluffy solid (Part B compound, 208 mg, 68%).

C.




25


To Part B compound (100 mg, 0.276 mmol) in 3 ml THF was added a solution of $\text{LiOH}\cdot\text{H}_2\text{O}$ (30 mg, 0.71 mmol) in 1 ml H_2O dropwise and mixture stirred overnight. The mixture was acidified with 1N HCl, extracted into EtOAc, the combined organic layer washed with brine, dried (Na_2SO_4), and evaporated to yield ~100 mg of the crude acid which was used as such for reduction.

Benzoxazole carboxylic acid obtained above (45 mg, 0.13 mmol) was dissolved in 4 ml THF. To this was added N-methylmorpholine (30 μ l, 0.3 mmol) followed by isobutylchloroformate (20 μ l, 0.15 mmol) dropwise. The mixture became turbid within minutes. The mixture was allowed to stir for 2 h, filtered through a cotton plug and rinsed with THF. To the filtrate was added solid NaBH₄ (20 mg, 0.53 mmol) followed by MeOH (dropwise, 0.5 ml). Vigorous effervescence ensued following NaBH₄ addition. The mixture was stirred for 2 h, quenched with 1N HCl, extracted into EtOAc (x2), the combined organic layer washed with brine, dried (Na₂SO₄), evaporated to yield a residue which was purified by PrepHPLC (YMC S5 ODS 20x250 mm; 10 min gradient; 40%B to 100%B) to obtain 10 mg of Part C compound (23%).

D.



product mixture (Part D1 compound) which was used as such for carbamate synthesis.




5

To above secondary amine (Part D1 compound) dissolved in CH_2Cl_2 (2 ml) was added sequentially pyridine (20 μl , 0.248 mmol) and a solution of 4-methoxyphenyl-chloroformate (20 mg, 0.107 mmol) in 0.2 ml CH_2Cl_2 . The reaction mixture was allowed to stir for 15 min, diluted with CH_2Cl_2 , washed with 1N HCl, brine, dried (Na_2SO_4), evaporated to yield a residue which was purified by PrephPLC (YMC S5 ODS 20x250 mm; 10 min gradient; 70%B to 100%B) to yield 5 mg (28% for 3 steps) of Part D compound.

15

E.



20

To a solution of Part D compound (5.0 mg, 0.0084 mmol) in CH_2Cl_2 (1.5 ml) at room temperature was added TFA (0.5 ml) dropwise. The reaction was stirred for 3 h and concentrated. The residue was purified by PrephPLC (YMC S5 ODS 20 x 100 mm; 20 mL/min; 10 min continuous gradient from 30%B:70%A to 100%B where solvent A= 90:10:0.1 H_2O :MeOH:TFA and solvent B= 90:10:0.1 MeOH: H_2O :TFA) to yield 1 mg of title compound. $[M + H^+] = 542.33$.


25

^1H NMR (400 MHz, CDCl_3) δ 2.303 (s, 3H), 3.1-3.2 (br t, 2H), 3.3-3.4 (br t, 2H), 3.7720 (s, 3H), 4.0661 (d, $J=8.4$ Hz, 2H), 4.786 (d, $J_{AB} = 41$ Hz, 2H), 6.854 (dd, $J=8.8$, 5.3


30

Hz, 2H), 7.039 (dd, $J=11.4$, 8.8 Hz, 2H), 7.3202 (t, $J=9.2$ Hz, 1H), 7.4-7.52 (m, 4H), 7.6555 (d, $J=8.8$ Hz, 1H), 7.9-8.0 (m, 2H).

5

Example 2

A.




10

To a solution of Part D1 compound (260 mg, 0.58 mmol) and Et_3N (0.16 mL, 1.16 mmol, 2 equiv) in CH_2Cl_2 (20 mL) at r.t. was added a solution of phosgene (1.93M in toluene, 0.6 mL, 1.16 mmol, 2 equiv) and the mixture allowed to stir for 3 h. The mixture was washed with H_2O , organic layer dried (Na_2SO_4), evaporated and the residue purified by flash chromatography (100% CH_2Cl_2) to yield 70 mg (24%) of Part A compound.

20


B.



4-Bromophenol (2.2 mg, 0.013 mmol, 1.1 equiv) was dissolved in 0.1 mL anhydrous DMF. KOt-Bu (3.9 mg, 0.036, 3 equiv) was then added and the reaction mixture was stirred for 15 min. A solution of Part A compound (6 mg, 0.012 mmol, 1 equiv) in 0.1 mL DMF was then added. After 5 min, the mixture was evaporated, resuspended in 1

mL CH₂Cl₂ and purified by flash chromatography (30% EtOAc:hexanes). The purified ester was dissolved in 0.2 mL CH₂Cl₂ and treated with 0.02 mL TFA and the mixture was allowed to stir for 16 h. Evaporation followed by purification by preparative HPLC (YMC S5 ODS 20 x 100 mm; 10 min continuous gradient from 30%B:70%A to 100%B where solvent A= 90:10:0.1 H₂O:MeOH:TFA and solvent B= 90:10:0.1 MeOH:H₂O:TFA) to afford 1.1 mg (16%) of title compound. [M + H⁺] = 590.09/592.15

10


Example 3

15


The title compound was prepared in an analogous manner to that of Examples 1 and 2. [M + H⁺] = 554.24

Example 4

20



A.




25

NaCN (442 mg, 9 mmol, 1.1 equiv) was dispersed in 6 mL DMSO and heated at 140°C for 30 min. To this solution was added (5-methyl-2-phenyl-4-oxazolyl)methyl chloride (1.7 gm, 8.2 mmol, prepared according to Malamas, Michael S. et al. *J. Med. Chem.* 39 (1); 1996;

30

237-245) in 5 mL DMSO and the reaction mixture was stirred at 120°C for 15 min. The mixture was poured into water, extracted with EtOAc (20 mL x 3), and the combined organic layer washed with brine (20 mL x 3), and
5 evaporated to provide a residue which was purified by flash chromatography (30% EtOAc:hexanes) to afford 600 mg (37%) of Part A compound as a yellow solid.

B.




10

Part B compound was prepared from Part A compound in a manner analogous to the sequence describing the synthesis of Example 1 Part D compound.

15

C.




Part B compound (6 mg, 0.0189 mmol), glycine
20 methyl ester hydrochloride (3.6 mg, 0.028 mmol, 1.5 equiv), and NaBH(OAc)₃ were stirred together in 0.2 mL CH₂Cl₂ at r.t. for 16 h after which the mixture was evaporated and the residue purified by preparative HPLC conditions (YMC ODS 20 x 100 mm flow rate = 20 mL/min; 10
25 min continuous gradient from 70%B:30%A to 100% B where solvent A = 90:10:0.1 H₂O:MeOH:TFA and solvent B = 90:10:0.1 MeOH:H₂O:TFA) to give 3 mg (40%) of the desired secondary amine.

To a solution of the secondary amine above (3 mg,
30 0.0077 mmol) and Et₃N (3 mg, 0.03 mmol, 4 equiv) in 1 mL CH₂Cl₂ was added 4-methoxyphenylchloroformate (3 mg, 0.015 mmol, 2 equiv) and the mixture stirred for 5 min. The


reaction mixture was evaporated to dryness and used as such for hydrolysis.

The crude methyl ester (from above) and LiOH.H₂O (2 mg, 0.047 mmol, 6 equiv) were stirred together in 10:1 MeOH:H₂O (0.5 mL) for 16 h. The mixture was acidified with 1N HCl and extracted into 1 mL EtOAc. Organic layer was evaporated and residue was purified by preparative HPLC conditions (YMC ODS 20 x 100 mm flow rate = 20 mL/min; 10 min continuous gradient from 70%B:30%A to 100% B where solvent A = 90:10:0.1 H₂O:MeOH:TFA and solvent B = 90:10:0.1 MeOH:H₂O:TFA). The desired fractions were neutralized with K₂CO₃, evaporated, and the pH of the residual solution adjusted to 7, and then extracted into EtOAc (2 mL) to yield 1.3 mg (32% overall) of title compound as a gum. [M + H⁺] = 528.18

Example 5




A.




4-Fluoro-3-nitrobenzoic acid (1.37 gm, 7.41 mmol) was dissolved in a methanolic solution of HCl and heated to 50°C for 16 h. Evaporation of the resulting mixture yielded 1.45 gm (7.29 mmol, 98%) of compound A as a colorless solid.

B.



A solution of 2M ethylamine in THF (1.2 mL, 2.4 mmol, 1.5 equiv.) was added to a solution of 4-fluoro-3-nitrobenzoic acid methyl ester (317 mg, 1.59 mmol) in 10 mL THF and the mixture was allowed to stir overnight. Evaporation followed by purification by flash chromatography (ISCO CombiFlash™, 10 gm silica; 0% to 100% EtOAc-hexanes) yielded 322 mg (93%) of compound B as a yellow solid.


C.



15

To a solution of compound B (125 mg, 0.56 mmol) in THF (6 mL) at r.t. was added a 2M solution of LiBH₄ (1.35 mL, 2.7 mmol, 4.8 equiv.) and the resulting mixture stirred overnight. The reaction was quenched with 1N HCl and extracted thoroughly into EtOAc (10 mL x 3). The combined organic layer was washed with brine, dried (Na₂SO₄), and evaporated to yield an orange residue which was purified by flash chromatography (ISCO CombiFlash™, 10 gm silica; 0% to 100% EtOAc-hexanes) to afford a yellow solid (compound C) weighing 67 mg (60%).

D.




30

To a suspension of the Dess-Martin sulfurane reagent (1.7 gm, 4 mmol, 1.5 equiv.) in CH₂Cl₂ (30 mL) was added a solution of 4-ethylamino-3-nitrobenzyl alcohol (compound C, 526 mg, 2.68 mmol, 1 equiv.) in 20 mL CH₂Cl₂


and the resulting mixture was stirred for 16 h. The reaction mixture was diluted with 50 mL ether and treated with 50 mL of 1:1 aqueous solution of NaHCO_3 :sodium thiosulfate for 1h. The resulting clear solution was
5 extracted thoroughly with EtOAc (50 mL x 3) and the combined organic layer was washed with brine, dried (Na_2SO_4), and evaporated to yield a residue which was chromatographed (ISCO CombiFlash™, 35 gm silica; 0% to
100% EtOAc-hexanes) to yield 348 mg (67%) of compound D
10 as a yellow solid.

E.



15 4-Ethylamino-3-nitrobenzaldehyde (compound D) (348 mg, 1.79 mmol), glycine methyl ester hydrochloride (675 mg, 5.38 mmol, 3 equiv.), sodium triacetoxyborohydride (1.76 gm, 8.34 mmol, 4.6 equiv.), Et_3N (1.5 mL, 10.8 mmol, 6 equiv.), and 1,2-dichloroethane (50 mL) were
20 stirred together at 55°C for 2 h. The reaction mixture was partitioned between CH_2Cl_2 and saturated aqueous NaHCO_3 and the aq. layer extracted with CH_2Cl_2 (50 mL x 2). The combined organic layer was washed with brine, dried (Na_2SO_4), evaporated and purified by flash
25 chromatography (ISCO CombiFlash™, 35 gm silica; 0% to 100% EtOAc-hexanes) to yield 417 mg (87%) of compound E as a red oil.

F.




30

To compound E (208 mg, 0.78 mmol) in CH_2Cl_2 was added pyridine (100 μL , 1.24 mmol, 1.6 equiv.) followed by 4-methoxyphenylchloroformate (140 μL , 0.94 mmol, 1.2 equiv.) and the mixture was stirred for 1 h. Evaporation and purification by flash chromatography (ISCO CombiFlashTM, 10 gm silica; 0% to 100% EtOAc-hexanes) afforded 263 mg (81%) of compound F as a yellow oil (solidified to a yellow solid in the freezer).


10

G.



Compound F (66 mg, 0.158 mmol) was hydrogenated in the presence 10% Pd-C (30 mg) and MeOH (10 mL) for 2 h at atmospheric pressure and r.t. The reaction mixture was filtered and evaporated to yield 47 mg (77%) of compound G as a colorless oil.


H.



20


To 3-(2-methyl-5-phenyl-oxazol-4-yl)propanol (133 mg, 0.613 mmol) in acetone (2 mL) was added Jones reagent via a Pasteur pipette (~15 drops) and the resulting mixture stirred for 7 h at rt. Evaporation followed by purification by preparative HPLC (YMC S5 ODS reverse phase column; 20 x 100 mm; flow rate = 20 mL/min; 10 min continuous gradient from 30%B:70%A to 100%B where solvent A= 90:10:0.1 H_2O :MeOH:TFA and solvent B= 90:10:0.1 MeOH: H_2O :TFA) yielded 91 mg (64%) of a colorless oil (compound H).

I.



To a mixture of 3-(2-methyl-5-phenyl-oxazol-4-yl)propanoic acid (compound H), compound G, and HOAt in CH_2Cl_2 was added diisopropylcarbodiimide dropwise. After 3h, all amine was consumed and several products (>13) were seen by HPLC. The reaction mixture was evaporated to dryness and purified by preparative HPLC (YMC S5 ODS reverse phase column; 20 x 100 mm; flow rate = 20 mL/min; 10 min continuous gradient from 30%B:70%A to 100%B where solvent A= 90:10:0.1 H_2O :MeOH:TFA and solvent B= 90:10:0.1 MeOH: H_2O :TFA) to afford 10 mg (14%) of compound I as a colorless oil. Side products included the corresponding monoamides from the primary and secondary amines, DIC adducts and the DIC adduct of a monoamide. $[\text{M} + \text{H}^+] = 583.10$.

J.




20

To a solution of compound I (10.0 mg, 0.017 mmol) in THF- H_2O (4:1, 2.5 mL) at room temperature was added $\text{LiOH} \cdot \text{H}_2\text{O}$ (11 mg, 0.262 mmol, 15 equiv.) all at once. The reaction mixture was stirred at room temperature for 3 h, acidified to pH ~4, and extracted into EtOAc (10 mL x 2). The combined organic layer was washed with brine, dried (Na_2SO_4) and evaporated to yield a colorless oil which was purified by preparative HPLC (YMC S5 ODS reverse phase


column; 20 x 100 mm; flow rate = 20 mL/min; 10 min continuous gradient from 30%B:70%A to 100%B where solvent A= 90:10:0.1 H₂O:MeOH:TFA and solvent B= 90:10:0.1 MeOH:H₂O:TFA) 3.4 mg (35%) of title compound as a colorless oil. [M + H⁺] = 569.17.

Example 6




10

A.



To a mixture of 3-(2-methyl-5-phenyl-oxazol-4-yl)acetic acid (Maybridge, 39 mg, 0.18 mmol, 1.16 equiv.) and Example 5 compound G (60 mg, 0.155 mmol) in CH₃CN (7 mL) was added benzotriazol-1-yloxy-tris(dimethylamino)-phosphonium hexafluorophosphate (125 mg, 0.28 mmol, 1.82 equiv.) and the resulting mixture stirred for 16 h. The reaction mixture was evaporated to dryness and purified by preparative HPLC (YMC S5 ODS reverse phase column; 20 x 100 mm; flow rate = 20 mL/min; 10 min continuous gradient from 30%B:70%A to 100%B where solvent A= 90:10:0.1 H₂O:MeOH:TFA and solvent B= 90:10:0.1 MeOH:H₂O:TFA) followed by flash chromatography (ISCO CombiFlashTM, 10 gm silica; 0% to 20% MeOH-CH₂Cl₂) to afford 4 mg (5%) of compound A as a brown oil. [M + H⁺] 569.11.


B.




To a solution of compound A (4.0 mg, 0.007 mmol) in THF-H₂O (4:1, 1.2 mL) at room temperature was added LiOH·H₂O (6 mg, 0.14 mmol, 20 equiv.) all at once. The reaction mixture was stirred at room temperature for 1 h, acidified to pH ~ 2, and extracted into EtOAc (10 mL x 2). The combined organic layer was washed with brine, dried (Na₂SO₄) and evaporated to yield a colorless oil which was purified by preparative HPLC (YMC S5 ODS reverse phase column; 20 x 100 mm; flow rate = 20 mL/min; 10 min continuous gradient from 30%B:70%A to 100%B where solvent A= 90:10:0.1 H₂O:MeOH:TFA and solvent B= 90:10:0.1 MeOH:H₂O:TFA) to afford 1.7 mg (44%) of title compound as a yellow oil. [M + H⁺] = 555.09.

¹H NMR (400 MHz, CDCl₃) δ 1.5879 (t, J=6.6 Hz, 3H), 2.4914 (s, 3H), 3.7467 (br s, 5H), 4.4992 (d, J=10.12 Hz, 2H), 4.69-4.72 (m, 3H), 4.8426 (s, 1H), 6.8240 (dd, J=8.8, 6.6 Hz, 2H), 6.98-7.04 (m, 2H), 7.37-7.42 (m, 3H), 7.48-7.6 (m, 2H), 7.86-7.85 (m, 3H).

Example 7




A.



5 Reference: B. Hulin et al. *J. Med. Chem.* **1996**,
39, 3897-3907.


10 To a slurry of cuprous oxide (55 mg, 0.385 mmol, 0.67 equiv) in 1 mL pyridine was added a solution of the compound A1 (prepared as described in B. Hulin et al. *J. Med. Chem.* **1996**, 39, 3897-3907, 113 mg, 0.577 mmol, 1 equiv) in 1 mL pyridine followed by a solution of 3-iodo-4-hydroxybenzaldehyde (138 mg, 0.585 mmol, 1 equiv) in 0.5 mL pyridine.

15



20 Bis(triphenylphosphine)palladium (II) chloride (9 mg, 0.02 equiv) was added as a solid and the mixture was heated to reflux for 3 h. The reaction mixture was evaporated in vacuo, taken up in EtOAc (20 mL), washed with 1N HCl (10 mL x 2), brine, dried (Na₂SO₄), filtered, and evaporated under reduced pressure to yield a dark
25 residue which was purified by flash chromatography (20% EtOAc-hexanes) to afford 76 mg (42%) of compound A as a yellow solid.

B.



30

To a mixture of compound A (65 mg, 0.205 mmol), glycine methyl ester hydrochloride (83 mg, 0.66 mmol, 3.2 equiv) and dichloroethane (10 mL) was added Et₃N (150 μ L, 0.75, 3.7 equiv) followed by NaBH(OAc)₃ (90 mg, 0.427 mmol, 2 equiv) and the resulting mixture allowed to stir for 12 h at rt. A second portion of NaBH(OAc)₃ (90 mg, 0.427 mmol, 2 equiv) was added at this point and the mixture stirred for a further 12 h. The mixture was diluted with CH₂Cl₂ (20 mL), washed with sat. aq. NaHCO₃, brine, dried (Na₂SO₄), and evaporated to yield 84 mg of the crude secondary amine which was used as such for the next reaction.


To a solution of secondary amine above (21.0 mg, 0.054 mmol) in CH₂Cl₂ (3 mL) at room temperature was added pyridine (13 μ L, 0.161 mmol, 3 equiv.) followed by 4-methylphenylchloroformate (13 μ L, 0.0905 mmol, 1.7 equiv) and the mixture stirred for 3.5 h. The reaction mixture was washed with 1N HCl (1 mL), brine (1 mL), dried (Na₂SO₄), and evaporated in vacuo to yield a yellow oil which was used as such for hydrolysis. [M + H⁺] = 525.07.

The crude ester above was dissolved in 4:1 THF:H₂O (5 mL) and LiOH.H₂O (10 mg, 0.24 mmol, 4.4 equiv) added all at once. After stirring at r.t. for 2 h, the mixture was acidified with 1N HCl and extracted into EtOAc (5 mL x 3). The combined organic layer was washed with brine, dried (Na₂SO₄), and evaporated to yield a residue which was purified by preparative HPLC (YMC S5 ODS reverse phase column; 30 x 75 mm; flow rate = 20 mL/min; 10 min continuous gradient from 70%B:30%A to 100%B where solvent A= 90:10:0.1 H₂O:MeOH:TFA and solvent B= 90:10:0.1 MeOH:H₂O:TFA) to afford 22.7 mg (82%) of the desired product as a yellow oil. [M + H⁺] = 511.07.

¹H NMR (400 MHz, CDCl₃) δ 2.2270 (s, 3H), 2.3094 (s, 3H), 3.9253 (d, J=23.7 Hz, 2H), 3.9692 (s, 2H), 4.62222 (d, J_{AB}=51 Hz, 2H), 6.4540 (d, J=5.72 Hz, 1H), 6.8909 (dd,


J=8.4, 4.0 Hz, 2H), 7.05-7.2 (m, 3H), 7.26-7.44 (m, 5H), 7.85-7.9 (m, 2H).

Example 8




The title compound was prepared in a manner analogous to Example 7. $[M + H^+] = 527.05$.

Example 9



A.




To a mixture of indole-4-carboxylic acid methyl ester (100 mg, 0.57 mmol), sodium hydride (60% dispersion, 30 mg, 0.855 mmol) in 5 mL anhydrous DMF was added 2-(5-methyl-2-phenyloxazol-4-yl)ethanol methanesulfonate (170 mg, 0.57 mmol) in 5 mL anhydrous DMF dropwise, and the mixture was then heated to reflux for 3 h. The reaction mixture was partitioned between H_2O (100 mL) and CH_2Cl_2 (100 mL). The aqueous phase was extracted with CH_2Cl_2 (2 x 50 mL). The combined organic extracts were washed with brine, dried (Na_2SO_4) and

concentrated in vacuo. The residue was chromatographed (SiO₂; 70:30 Hex:EtOAc) to obtain compound A (220 mg, 99%) as yellow solid.

5


B.



Compound A from above was dissolved in anhydrous THF (3 ml) under Ar. LAH (1.0 M in THF, 1.39 mL, 1.39 mmol) was added and the reaction mixture was heated under reflux overnight. The reaction mixture was partitioned between H₂O (100 mL) and EtOAc (100 mL). The aqueous phase was extracted with EtOAc (2 x 50 mL). The combined organic extracts were washed with brine, dried (Na₂SO₄) and concentrated in vacuo. The residue was chromatographed (SiO₂, 100% EtOAc) to obtain compound B (200 mg, 99%) as yellow solid.

20

C.




To a mixture of silica (SiO₂, 100 mg) and PCC (136 mg, 0.63 mmol) in 1 mL CH₂Cl₂, was added compound B (200 mg, 0.63 mmol) in 0.5 mL CH₂Cl₂, and the reaction was stirred at rt for 15 min. The reaction mixture was then poured onto a column (SiO₂, 50:50 EtOAc:Hex) to obtain the desired aldehyde as a yellow solid (110 mg, 50%).

The obtained aldehyde (110 mg, 0.63 mmol) was then dissolved in 1 mL CH₂Cl₂ and to this solution was added sodium triacetoxyborohydride (135mg, 0.318 mmol) and glycine methyl ester (60 mg, 0.47 mmol), and the reaction was stirred at rt overnight. The solution was then

poured onto a silica column eluting with 100% EtOAc to yield compound C as a white solid (100 mg, 75%).

D.



5

Compound C (20 mg, 0.048 mmol) and 4-methoxyphenyl chloroformate (14 mg, 0.72 mmol) were dissolved in 1 mL CH₂Cl₂, then Et₃N was added and the reaction was stirred at rt for 15 min. The aqueous phase was washed with NH₄Cl (2 x 2 mL), dried with Na₂SO₄, and then evaporated in vacuo. The residue was then dissolved in 10:1 MeOH:H₂O (2 mL), treated with LiOH (15 mg, 0.75 mmol), and the reaction was stirred at rt for 2 h. Volatiles were removed in vacuo and the residue was acidified to pH 2 with aqueous 1 M HCl, then extracted with EtOAc (3 x 2 mL). The combined organic extracts were dried (Na₂SO₄) and then concentrated in vacuo. The crude product was purified by preparative HPLC (YMC 5 ODS 50 x 250 mm column; flow rate = 25 mL/min; continuous 20 min gradient from 70:30 B:A to 100% B, where A = 90:10:0.1 H₂O:MeOH:TFA and B = 90:10:0.1 MeOH:H₂O:TFA) to afford title compound (8.8 mg, 23% in two steps) as a colorless oil. [M + H⁺] = 540.2

25

¹H NMR (400 MHz, CDCl₃) Rotamers δ 1.58/1.63 (s, 3H), 2.98/2.92 (t, J=4Hz, 2H), 3.77/3.79 (s, 3H), 4.04/4.07 (s, 2H), 4.18/4.34 (t, J=8Hz, 2H), 4.73/4.83 (s, 2H), 6.375/6.405 (d, J=4Hz, 1H), 6.84-6.92 (m, 3H), 7.04-7.27 (m, 3H), 7.43-7.53 (m, 4H), 7.95-7.98 (m, 2H), 10.80 (br. s, 1H).


30

Examples 10 to 16


The following compounds were prepared in a manner analogous to Example 9:

5

Example 10, $[M + H^+] = 524.3$




10 Example 11, $[M + H^+] = 554.2$




Example 12, $[M + H^+] = 538.2$


15




Example 13, $[M + H^+] = 538.2$



5 Example 14, $[M + H^+] = 554.2$




Example 15, $[M + H^+] = 524.4$



10


Example 16, $[M + H^+] = 540.3$



15

What is Claimed is:

1. A compound which has the structure



5

wherein m is 0, 1 or 2; n = 0, 1 or 2;

Q is C or N

A is $(\text{CH}_2)_x$ where x is 1 to 5; or A is $(\text{CH}_2)_{x^1}$, where x^1 is 2 to 5, with an alkenyl bond or an alkynyl bond embedded in the chain; or A is $-(\text{CH}_2)_{x^2}-\text{O}-(\text{CH}_2)_{x^3}-$ where x^2 is 0 to 5 and x^3 is 0 to 5, provided that at least one of x^2 and x^3 is other than 0,

X_1 is CH or N

X_2 is CR^a , NR^b , O or S;

15

X_3 is CR^c or NR^d ;

X_4 is CR^e , NR^f , O or S, wherein R^a , R^c and R^e are the same or different and are independently selected from a single bond, H, alkyl, alkoxy, aryl, cycloalkyl, amino or substituted amino, and R^b , R^d and R^f are the same or different and are independently selected from a single bond, H, alkyl, aryl, heteroaryl, cycloalkyl or cycloheteroalkyl, provided that at least one of X_2 , X_3 and

X_4 is —N— ;

E is O, S, NR^g or CR^h ;

25

M is NR^i or CR^j ;

G is O, S, NR^k or CR^l , wherein R^g , R^i and R^k are the same or different and are independently selected from a single bond, H, alkyl, aryl, cycloalkyl, heteroaryl or cycloheteroalkyl; and R^h , R^j and R^l are the same or different and are independently selected from a single bond, H, alkyl, alkoxy, aryl, cycloalkyl, amino or substituted amino; provided that at least one of E, M and G is other than CH or C; and where E, M and G are each

30

—N—, then A is other than —CH₂O—; and where in each of X₁ through X₄ as defined above, C may include CH;

R¹ is H or alkyl;

R² is H, alkyl, alkoxy, halogen, amino or
5 substituted amino;

R^{2a}, R^{2b} and R^{2c} are the same or different and are selected from H, alkyl, alkoxy, halogen, amino or substituted amino;


R³ is selected from aryloxycarbonyl,
10 alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, alkyl(halo)aryloxycarbonyl, alkyloxy(halo)aryloxy-carbonyl, cycloalkylaryloxycarbonyl, cycloalkyloxyaryloxycarbonyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino,
15 alkoxycarbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, heteroarylalkenyl, hydroxyalkyl, alkoxy, alkoxyaryloxycarbonyl,
20 arylalkyloxycarbonyl, alkylaryloxycarbonyl, haloalkoxyaryloxycarbonyl, alkoxycarbonylaryloxycarbonyl, aryloxyaryloxycarbonyl, heteroaryloxyarylalkyl, aryloxyarylalkyloxycarbonyl, arylalkenyloxycarbonyl, aryloxyalkyloxycarbonyl, arylalkylsulfonyl,
25 arylthiocarbonyl, arylalkenylsulfonyl, heteroarylsulfonyl, arylsulfonyl, heteroarylalkoxy-carbonyl, heteroarylalkyloxyarylalkyl, arylalkenylarylalkyl, heteroaryloxyarylalkyl, arylalkenylheteroarylalkyl, or polyhaloalkylaryloxy-
30 carbonyl;

Y is CO₂R⁴ (where R⁴ is H or alkyl, or a prodrug ester) or Y is a C-linked 1-tetrazole, a phosphinic acid of the structure P(O)(OR^{4a})R⁵ (R⁵ is alkyl or aryl, or a phosphonic acid of the structure P(O)(OR^{4a})₂ (where R^{4a} is
35 H or a prodrug ester).


$(\text{CH}_2)_x$, $(\text{CH}_2)_{x^1}$, $(\text{CH}_2)_{x^2}$, $(\text{CH}_2)_{x^3}$, $(\text{CH}_2)_m$, and $(\text{CH}_2)_n$ may be optionally substituted with 1, 2 or 3 substituents;

including all stereoisomers thereof, a prodrug ester thereof, and a pharmaceutically acceptable salt thereof.


2. A compound having the structure



3. The compound as defined in Claim 1 having the structure



4. The compound as defined in Claim 1 having structure



5. The compound as defined in Claim 1 wherein $(\text{CH}_2)_x$, $(\text{CH}_2)_{x^1}$, $(\text{CH}_2)_{x^2}$, $(\text{CH}_2)_{x^3}$ are alkylene, alkenylene, allenyl, or alkynylene.

25

6. The compound as defined in Claim 1 wherein X_1 is CH.

7. The compound as defined in Claim 1 wherein X_1 is N.

8. The compound as defined in Claim 1 wherein M is C.


9. The compound as defined in Claim 1 wherein M is N.

10. The compound as defined in Claim 1 wherein M is C, E is N or C, and G is O or N.

11. The compound as defined in Claim 1 wherein M is N and E and G are C.


12. The compound as defined in Claim 1 wherein m is 1 and x is 1, 2 or 3.

13. The compound as defined in Claim 1 wherein



25


14. The compound as defined in Claim 1 wherein R^3 is




30 wherein Z is alkoxy, alkyl or halo.






15. The compound as defined in Claim 1 wherein Y is CO_2R^4 .

5 16. The compound as defined in Claim 1 wherein







17. The compound as defined in Claim 1 having the
10 structure






5



10



18. A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

5 19. A method for lowering blood glucose levels which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

10 20. A method for treating diabetes which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

15 21. A method for treating a premalignant disease, an early malignant disease, a malignant disease, or a dysplastic disease, which comprises administering to a patient in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

20 22. A pharmaceutical combination comprising a compound as defined in Claim 1 and a lipid-lowering agent, a lipid modulating agent, an antidiabetic agent, an anti-obesity agent, an antihypertensive agent, a
25 platelet aggregation inhibitor, and/or an antiosteoporosis agent.

30 23. The pharmaceutical combination as defined in Claim 22 comprising said compound and an antidiabetic agent.

24. The combination as defined in Claim 23 wherein the antidiabetic agent is 1, 2, 3 or more of a biguanide, a sulfonyl urea, a glucosidase inhibitor, a
35 PPAR γ agonist, a PPAR α/γ dual agonist, an SGLT2 inhibitor, a DP4 inhibitor, an α P2 inhibitor, an insulin

sensitizer, a glucagon-like peptide-1 (GLP-1), insulin and/or a meglitinide.

25. The combination as defined in Claim 24
5 wherein the antidiabetic agent is 1, 2, 3 or more of metformin, glyburide, glimepiride, glipyrider, glipizide, chlorpropamide, gliclazide, acarbose, miglitol, pioglitazone, troglitazone, rosiglitazone, insulin, Gl-
262570, isaglitazone, JTT-501, NN-2344, L895645, YM-440,
10 R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-HO39242, GW-409544, KRP297, AC2993, LY315902, P32/98 and/or NVP-DPP-728A.

26. The combination as defined in Claim 23
15 wherein the compound is present in a weight ratio to the antidiabetic agent within the range from about 0.001 to about 100:1.

27. The combination as defined in Claim 22
20 wherein the anti-obesity agent is a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, a thyroid receptor agonist, an α 2 inhibitor and/or an anorectic agent.

28. The combination as defined in Claim 27
25 wherein the anti-obesity agent is orlistat, ATL-962, AJ9677, L750355, CP331648, sibutramine, topiramate, axokine, dexamphetamine, phentermine, phenylpropanolamine, and/or mazindol.

29. The combination as defined in Claim 22
30 wherein the lipid lowering agent is an MTP inhibitor, an HMG CoA reductase inhibitor, a squalene synthetase inhibitor, a fibric acid derivative, an upregulator of
35 LDL receptor activity, a lipoxxygenase inhibitor, or an ACAT inhibitor.

30. The combination as defined in Claim 29 wherein the lipid lowering agent is pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, itavastatin, visastatin, fenofibrate, 5 gemfibrozil, clofibrate, avasimibe, TS-962, MD-700, cholestagel, niacin and/or LY295427.

31. The combination as defined in Claim 29 wherein the compound is present in a weight ratio to the 10 lipid-lowering agent within the range from about 0.001:1 to about 100:1.

32. The combination as defined in Claim 22 wherein the antihypertensive agent is an ACE inhibitor, 15 angiotensin II receptor antagonist, NEP/ACE inhibitor, calcium channel blocker and/or β -adrenergic blocker.

33. The combination as defined in Claim 32 wherein the antihypertensive agent is an ACE inhibitor 20 which is captopril, fosinopril, enalapril, lisinopril, quinapril, benazepril, fentiapril, ramipril or moexipril; an NEP/ACE inhibitor which is omapatrilat, [S[(R*,R*)]-hexahydro-6-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-2,2-dimethyl-7-oxo-1H-azepine-1-acetic acid (gemopatrilat), 25 CGS 30440 or MD 100240;

an angiotensin II receptor antagonist which is irbesartan, losartan or valsartan;

amlodipine besylate, prazosin HCl, verapamil, nifedipine, nadolol, propranolol, carvedilol, or 30 clonidine HCl.

34. The combination as defined in Claim 22 wherein the platelet aggregation inhibitor is aspirin, clopidogrel, ticlopidine, dipyridamole or ifetroban. 35

35. A method for treating insulin resistance, hyperglycemia, hyperinsulinemia, or elevated blood levels

of free fatty acids or glycerol, hyperlipidemia, obesity, Syndrome X, dysmetabolic syndrome, inflammation, diabetic complications, impaired glucose homeostasis, impaired glucose tolerance, hypertriglyceridemia or
5 atherosclerosis which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a pharmaceutical combination as defined in Claim 23.

10 36. The method as defined in Claim 21 wherein the disease is a liposarcoma or an epithelial tumor.

37. The method as defined in Claim 36 wherein the epithelial tumor is a tumor of the breast, prostate,
15 colon, ovaries, stomach or lung.

38. The method as defined in Claim 21 wherein the disease is ductal carcinoma in situ of the breast, lobular carcinoma in situ of the breast, fibroadenoma of
20 the breast, or prostatic intraepithelial neoplasia.

39. A method for treating irritable bowel syndrome, Crohn's disease, gastric ulceritis or osteroporosis, or psoriasis, which comprises
25 administering to a mammalian species in need of treatment a therapeutically effective amount of a compound as defined in Claim 1.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/35704

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 263/56; A61K 31/421

US CL : 548/217; 514/375

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 548/217; 514/375

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A -	US 6,136,831 A (AOTSUKA) 24 October 2000 (24.10.2000), column 2, lines 48-67.	17

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

24 January 2003 (24.01.2003)

Date of mailing of the international search report

13 FEB 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Felicia D. Roberts for Sonya Wright

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/35704

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claim Nos.: 1-16 and 18-39
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Please See Continuation Sheet
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

INTERNATIONAL SEARCH REPORT

PCT/US02/35704

Continuation of Box I Reason2:

In these claims, the numerous variables (e.g. A, E, G, Q, M, Y, X1, X2, X3, X4, etc. . .) and their voluminous complex meanings and their seemingly endless permutations and combinations and the numerous provisos, make it virtually impossible to determine the full scope and complete meaning of the claimed subject matter. As presented, the claimed subject matter cannot be regarded as being a clear and concise description for which protection is sought and as such the listed claims do not comply with the requirements of PCT article 6. Thus it is impossible to carry out a meaningful search on same. A search will be made on the first discernable invention, which is the first four structures of claim 17.

